A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
- Conditions
- Urothelial Cancer
- Interventions
- Device: Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)
- Registration Number
- NCT03390504
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\[L\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).
- Detailed Description
A study of erdafitinib versus standard of care, consisting of chemotherapy (docetaxel or vinflunine) or anti-PD-(L) 1 agent pembrolizumab, in participants with advanced urothelial cancer and selected FGFR aberrations who have progressed on or after 1 or 2 prior treatments, at least 1 of which includes an anti-PD-(L) 1 agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2). It will consist of screening, treatment phase (from randomization until disease progression, intolerable toxicity, withdrawal of consent or decision by investigator to discontinue treatment, post-treatment follow-up (from end-of-treatment to participants death, withdraws consent, lost to follow-up study completion for the respective cohort, whichever comes first). The study will have long term extension (LTE) period after clinical cutoff date is achieved for final analysis of each cohort and participants eligible in the opinion of the investigator, will continue to benefit from the study intervention. Efficacy, pharmacokinetics, biomarkers, patient reported outcomes, medical resource utilization and safety will be assessed.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 629
- Histologic demonstration of transitional cell carcinoma of the urothelium. Minor components ( less than [<] 50 percent [%] overall) of variant histology such as glandular or squamous differentiation, or evolution to more aggressive phenotypes such as sarcomatoid or micropapillary change are acceptable
- Metastatic or surgically unresectable urothelial cancer
- Documented progression of disease, defined as any progression that requires a change in treatment, prior to randomization
- Cohort 1: Prior treatment with an anti-PD-(L) 1 agent as monotherapy or as combination therapy; no more than 2 prior lines of systemic treatment. Cohort 2: No prior treatment with an anti-PD-(L) 1 agent; only 1 line of prior systemic treatment. Subjects who received neoadjuvant or adjuvant chemotherapy and showed disease progression within 12 months of the last dose are considered to have received systemic therapy in the metastatic setting.
- A woman of childbearing potential who is sexually active must have a negative pregnancy test (beta human chorionic gonadotropin [beta hCG]) at Screening (urine or serum)
- Participants must meet appropriate molecular eligibility criteria
- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
- Adequate bone marrow, liver, and renal function
- Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 30 days prior to randomization
- Active malignancies (that is, requiring treatment change in the last 24 months). The only allowed exceptions are: urothelial cancer, skin cancer treated within the last 24 months that is considered completely cured, localized prostate cancer with a gleason score of 6 (treated within the last 24 months or untreated and under surveillance) and localized prostate cancer with a gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence.
- Symptomatic central nervous system metastases
- Received prior fibroblast growth factor receptor (FGFR) inhibitor treatment
- Known allergies, hypersensitivity, or intolerance to erdafitinib or its excipients
- Current central serous retinopathy (CSR) or retinal pigment epithelial detachment of any grade.
- History of uncontrolled cardiovascular disease
- Impaired wound healing capacity defined as skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort 1 (Arm 1A): Erdafitinib Erdafitinib Participants will be screened based on Fibroblast Growth Factor Receptor Inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-\[L\] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events \[AEs\]). Participants who enter in Long-term extension (LTE) phase will continue to receive the erdafitinib tablet as per investigator's decision. Cohort 1 (Arm 1A): Erdafitinib Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA) Participants will be screened based on Fibroblast Growth Factor Receptor Inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-\[L\] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events \[AEs\]). Participants who enter in Long-term extension (LTE) phase will continue to receive the erdafitinib tablet as per investigator's decision. Cohort 1 (Arm 1B): Vinflunine or Docetaxel Vinflunine Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-\[L\] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m\^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive Vinflunine or Docetaxel until the participant can commercially receive chemotherapy within the local healthcare system. Cohort 1 (Arm 1B): Vinflunine or Docetaxel Docetaxel Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-\[L\] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m\^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive Vinflunine or Docetaxel until the participant can commercially receive chemotherapy within the local healthcare system. Cohort 1 (Arm 1B): Vinflunine or Docetaxel Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA) Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-\[L\] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m\^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive Vinflunine or Docetaxel until the participant can commercially receive chemotherapy within the local healthcare system. Cohort 2 (Arm 2A): Erdafitinib Erdafitinib Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-\[L\] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs). Participants who enter in LTE phase will continue to receive the erdafitinib tablet as per investigator's decision. Cohort 2 (Arm 2A): Erdafitinib Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA) Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-\[L\] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs). Participants who enter in LTE phase will continue to receive the erdafitinib tablet as per investigator's decision. Cohort 2 (Arm 2B): Pembrolizumab Pembrolizumab Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-\[L\] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive the pembrolizumab until 2 years after the first dose of pembrolizumab (at start of study) or until the participant can commercially receive pembrolizumab within the local healthcare system, whichever comes first. Cohort 2 (Arm 2B): Pembrolizumab Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA) Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-\[L\] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive the pembrolizumab until 2 years after the first dose of pembrolizumab (at start of study) or until the participant can commercially receive pembrolizumab within the local healthcare system, whichever comes first.
- Primary Outcome Measures
Name Time Method Overall Survival (OS) From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months) Overall survival was measured from the date of randomization to the date of the participant's death.
- Secondary Outcome Measures
Name Time Method Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 From randomization (3 days prior to Cycle 1 Day 1) until disease progression or relapse from CR or death (maximum up to 51.7 months) PFS was defined as the time from the date of randomization to the date of disease progression or relapse from complete response (CR) based on investigator assessment using RECIST v 1.1, or death due to any cause, whichever occurred first. As per RECIST v 1.1, CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to less than (\<) 10 millimeters (mm). Progressive disease (PD) was defined as at least 20 percent (%) increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of greater than or equal to (\>=) 5 mm or appearance of at least 1 new lesion.
Objective Response Rate (ORR) Per RECIST Version 1.1 From start of the treatment (Day 1 Cycle 1) up to maximum of 51.7 months ORR was defined as the percentage of participants who achieved CR or partial response (PR) as determined by investigator per RECIST v1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Change From Baseline in Physical Functioning Scales of the Functional Assessment of Cancer Therapy - Bladder Cancer (FACT-Bl) Baseline up to Cycle 11 (each cycle was of 21 days) The FACT-Bl consisted of 39 items, with 5-point Likert scales, covering 5 primary domains: physical well-being, social/family well-being, emotional well-being, functional well-being and additional concerns for participants with bladder cancer. The response options ranged from 0 to 4 where, 0='Not at all" and 4= "very much." FACT-Bl total score ranged from 0 (worst) to 156 (best). The higher the score, the better the quality of life (QOL). The baseline value was defined as the value collected at the time closest to but prior to the randomization.
Time Until Symptom Deterioration Randomization (3 days prior to Cycle 1 Day 1) up to maximum of 51.7 months Time until symptom deterioration was defined as the first time to increase in urinary bladder cancer symptoms score from the day of randomization beyond a meaningful change threshold compared to baseline. The urinary bladder cancer symptom score was subset of FACT-Bl which included 3 items related to urinary symptoms, 5-point Likert scale. Response options ranged from 0 to 4, 0 = Not at all, 1= A little bit, 2= Somewhat, 3=Quite a bit, 4 = Very much. A response of 0 indicated no symptoms and 4 indicated severe symptoms. Total sum scores ranged from 0 to 12, higher scores indicate relatively poor quality of life.
Percentage of Participants With Shift From Baseline in Patient-Global Impression of Severity (PGIS) Baseline, 51.7 months The PGI-S was a single item patient-reported measure assessing participants' impression of severity in bladder cancer symptoms. It uses a 4-point Likert scale as follows: symptoms are: 0-"absent (no symptoms)", 1-"mild", 2-"moderate", 3="severe" and 4= "very severe". Percentage of participants with shift from baseline in PGIS score were reported. A negative shift from baseline in PGIS score indicated Improvement and positive shift from baseline in PGIS score indicated Worsening. The baseline value was defined as the value collected at the time closest to but prior to the randomization.
Change From Baseline in Utility Scale of the European Quality of Life-5 Dimensions-5 Levels Questionnaire (EQ-5D-5L) Baseline up to Cycle 11 (each cycle was of 21 days) The EQ-5D-5L was a generic measure of health status. The EQ-5D-5L was a 5-item questionnaire that assessed 5 domains included mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Health utility values generated from the EQ-5D generally range from 0 (a state as bad as being dead) to 1 (full health), with higher scores indicating better QoL. The EQ visual analog scale (VAS) recorded the patient's self-rated health on a VAS, ranged from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better QoL. The baseline value was defined as the value collected at the time closest to but prior to the randomization.
Change From Baseline in Visual Analog Scale (VAS) of the European Quality of Life-5 Dimensions-5 Levels Questionnaire (EQ-5D-5L) Baseline up to Cycle 11 (each cycle was of 21 days) The EQ-5D-5L was a generic measure of health status. The EQ-5D-5L was a 5-item questionnaire that assessed 5 domains included mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Health utility values generated from the EQ-5D generally range from 0 (a state as bad as being dead) to 1 (full health), with higher scores indicating better QoL. The EQ VAS recorded the patient's self-rated health on a VAS, ranged from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better QoL. The baseline value was defined as the value collected at the time closest to but prior to the randomization.
Duration of Response (DOR) as Per RECIST Version 1.1 From date of first documented response to date of first documented PD or death whichever occurred first (maximum up to 51.7 months) DOR was defined as time from the date of initial documentation of an overall response (CR or PR) to the date of first documented evidence of progressive disease (PD) (or relapse for participants who experience CR) or death. As per RECIST Version 1.1: CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of \>=5 mm or appearance of at least 1 new lesion.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) From start of the treatment (Day 1 Cycle 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (maximum up to 51.7 months) An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were the events between first dose of study drug and up to 30 days after last dose or before start of new anticancer therapy, whichever occurred first. All TEAEs including serious and non-serious events were reported in this outcome measure.
Number of Participants With Shift From Baseline Grade Less Than or Equal to (<=) 2 to Grade Greater Than or Equal to (>=) 3 Post-Baseline in Laboratory Parameter: Hematology From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months) Hematology parameters included: hemoglobin, platelet count, white blood cell (WBC) count, and absolute neutrophil count (ANC). According to national cancer institute (NCI)-common terminology criteria for adverse events (CTCAE) version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE and Grade 0= normal. In this outcome measure number of participants with shifts from baseline (BL) Grade \<= 2 to Grade \>=3 post-baseline in any of hematology parameters are reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only those categories in which at least one participant had data were reported in this outcome measure.
Number of Participants With Shift From Baseline Grade <= 2 to Grade >=3 Post-Baseline in Laboratory Parameter: Chemistry From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months) Chemistry parameters included: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, chloride, creatinine, bicarbonate, corrected calcium, magnesium, potassium, sodium, serum phosphate, serum parathyroid hormone. According to NCI-CTCAE version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE and Grade 0= normal. In this outcome measure number of participants with shifts from baseline (BL) Grade \<= 2 to Grade \>=3 post-baseline in any of chemistry parameters are reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only those categories in which at least one participant had data were reported in this outcome measure.
Number of Participants With Abnormalities in Electrocardiograms (ECG) Parameters Day 1 of Cycle 2 and 4 (Each Cycle 21 days) Number of participants with abnormalities in ECG parameters were reported. The ECG variables included heart rate, RR interval, PR interval, QRS interval, QT interval and QT corrected according to Fridericia's formula (QTcF). ECG abnormality criteria include: Heart rate: Low \<50 beats per minute (bpm); High \> 100 bpm, RR interval: Low \< 600 milliseconds (ms); High \> 1000 ms, QT interval: High \> 500 ms, QTc interval: High \> (450 ms for males, 470 ms for females); increase to \>500 ms.
Change From Baseline in Vital Signs: Weight Baseline, 51.7 months Changes from baseline in vital signs (weight) was reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug.
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Amsler Grid Test From baseline up to maximum of 51.7 months Number of participants with shift from baseline to worst post-baseline in Amsler grid test was reported. Baseline and post-baseline visit findings included normal, abnormal CS (clinically significant) and abnormal NCS (not clinically significant). Clinical significance was determined by investigator's assessment. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported.
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Visual Acuity From baseline up to maximum of 51.7 months Number of participants with shift from baseline to worst post-baseline in visual acuity (VA) was reported. Worst post-baseline was defined as the visual acuity value that resulted in the largest change from baseline value for either eye. Baseline value was considered for the eye that reported the worst-post baseline value. Baseline and post-baseline visit visual acuity findings included: \<= 20/30, \>20/30 to \<= 20/40, \>20/40 to \<= 20/80, \>20/80 to \<= 20/120, \>20/120 to \<= 20/160, \>20/160 to \<= 20/200, \>20/200. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening in visual acuity from baseline value to worst post-baseline measurement was reported.
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Optical Coherence Tomography: Subretinal Fluid From baseline up to maximum of 51.7 months Number of participants with shift from baseline to worst post-baseline in optical coherence tomography for subretinal fluid was reported. At the baseline visit, findings may have been absent or present/visible. At all post-baseline visits, findings were compared to baseline and results may have been increased, decreased, stable or resolved. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only category (shift from absent at baseline to increased at post-baseline) in which at least one participant had data for worsening post-baseline measurement was reported.
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Optical Coherence Tomography: Retinal Pigment Epithelium (RPE) Elevation From baseline up to maximum of 51.7 months Number of participants with shift from baseline to worst post-baseline in optical coherence tomography for RPE elevation was reported. At the baseline visit, findings may have been absent or present/visible. At all post-baseline visits, findings were compared to baseline and results may have been increased, decreased, stable or resolved. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported.
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Slit Lamp Biomicroscopy: Retinal Assessment From baseline up to maximum of 51.7 months Number of participants with shift from baseline to worst post-baseline in slit lamp biomicroscopy examination for retinal assessment was reported. Baseline and post-baseline visit findings included normal, abnormal CS and abnormal NCS. Clinical significance was determined by investigator's assessment. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported.
Oral Clearance (CL/F) of Erdafitinib Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle was of 21 days) Clearance was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes.
Area Under the Plasma Concentration-Time Curve From Time Zero to Time 't' (AUC[0-t]) of Erdafitinib Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle is of 21 days) Area under the plasma concentration time-curve from time zero to the time t (AUC\[0-t\]) was reported.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (344)
Hopital de la Timone
🇫🇷Marseille, France
Asklepios Klinik Altona
🇩🇪Hamburg, Germany
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
Universitatsklinikum Schleswig Holstein Campus Lubeck
🇩🇪Lubeck, Germany
Medizinische Fakultät Mannheim der Universität Heidelberg
🇩🇪Mannheim, Germany
Universitaetsklinikum Muenster
🇩🇪Muenster, Germany
Studienpraxis Urologie Drs. Feyerabend
🇩🇪Nuertingen, Germany
Caritas-Krankenhaus St. Josef
🇩🇪Regensburg, Germany
Universitaetsmedizin Rostock
🇩🇪Rostock, Germany
MVZ-Onkologie Velbert GbR
🇩🇪Velbert, Germany
Kliniken Nordoberpfalz AG/Klinikum Weiden
🇩🇪Weiden, Germany
Errikos Dunant Hospital Center
🇬🇷Athens, Greece
Athens Medical Center
🇬🇷Athens, Greece
Metropolitan General A E
🇬🇷Athens, Greece
University of Athens Medical School - Regional General Hospi
🇬🇷Athina, Greece
University Hospital Of Larissa
🇬🇷Larisa, Greece
University General Hospital of Rio Patras
🇬🇷Patras, Greece
Interbalkan European Medical Center
🇬🇷Thessaloniki, Greece
Istituti Ospitalieri di Cremona, AO di Cremona
🇮🇹Cremona, Italy
Oncologia Medica
🇮🇹Firenze, Italy
SPDC Villa Scassi
🇮🇹Genova, Italy
UOC Oncologia Ospedale Provinciale di Macerata
🇮🇹Macerata, Italy
IRST Meldola Forli
🇮🇹Meldola, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹Milano, Italy
European Institute of Oncology
🇮🇹Milano, Italy
IRCCS Ospedale San Raffaele
🇮🇹Milan, Italy
AOU Policlinico di Modena
🇮🇹Modena, Italy
IRCCS-Fondazione Pascale
🇮🇹Napoli, Italy
Ospedale Maggiore della Carita
🇮🇹Novara, Italy
Aou San Luigi Gonzaga
🇮🇹Orbassano, Italy
Istituto Oncologico Veneto Iov Irccs Padova
🇮🇹Padova, Italy
AOU di Parma
🇮🇹Parma, Italy
IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy
Ist. Clinici Scientifici Maugeri - Unità Operativa di Oncolo
🇮🇹Pavia, Italy
Azienda Ospedaliero Universitaria Pisana
🇮🇹Pisa, Italy
Usl 7 Siena - Ospedale Alta Valdelsa ASL TOSCANA SUD-EST
🇮🇹Poggibonsi (SI), Italy
Fondazione Policlinico Universitario A Gemelli IRCCS
🇮🇹Roma, Italy
Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte
🇮🇹Siena, Italy
Oncologia Medica-Città Della Salute E Della Scienza Di Torino
🇮🇹Torino, Italy
Azienda Ospedaliero - Universitaria Ospedali Riuniti
🇮🇹Torrette Di Ancona, Italy
Chiba Cancer Center
🇯🇵Chiba, Japan
Hirosaki University Hospital
🇯🇵Hirosaki, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Japan
Kagawa University Hospital
🇯🇵Kita Gun, Japan
Kobe City Medical Center General Hospital
🇯🇵Kobe, Japan
Dokkyo Medical University Saitama Medical Center
🇯🇵Koshigaya, Japan
Aso Co.,Ltd Iizuka Hospital
🇯🇵Matsuyama, Japan
University of Miyazaki Hospital
🇯🇵Miyazaki, Japan
Nagano Municipal Hospital
🇯🇵Nagano, Japan
Aichi Cancer Center Hospital
🇯🇵Nagoya Shi, Japan
Osaka International Cancer Institute
🇯🇵Osaka City, Japan
Kindai University Hospital
🇯🇵Osaka-Sayama, Japan
Osaka City University Hospital
🇯🇵Osaka, Japan
Gunma Prefectural Cancer Center
🇯🇵Ota, Japan
Kitasato University Hospital
🇯🇵Sagamihara, Japan
Toho University Sakura Medical Center
🇯🇵Sakura, Japan
National Hospital Organization Hokkaido Cancer Center
🇯🇵Sapporo, Japan
Tokyo Women's Medical University Hospital
🇯🇵Shinjuku-ku, Japan
Toranomon Hospital
🇯🇵Tokyo, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
University of Tsukuba Hospital
🇯🇵Tsukuba, Japan
Instituto Portugues de Oncologia
🇵🇹Porto, Portugal
Altai Regional Oncology Dispensary
🇷🇺Barnaul, Russian Federation
Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine
🇷🇺Chelyabinsk, Russian Federation
Irkutsk Regional Oncology Dispensary
🇷🇺Irkutsk, Russian Federation
Hosp. de La Santa Creu I Sant Pau
🇪🇸Barcelona, Spain
Hosp. San Pedro de Alcantara
🇪🇸Caceres, Spain
Hosp Reina Sofia
🇪🇸Córdoba, Spain
Hosp. Univ. Virgen de Las Nieves
🇪🇸Granada, Spain
Complejo Hospitalario de Jaen
🇪🇸Jaén, Spain
Hosp. Univ. Insular de Gran Canaria
🇪🇸Las Palmas de Gran Canaria, Spain
Hosp. Univ. Lucus Augusti
🇪🇸Lugo, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Hosp. Univ. La Paz
🇪🇸Madrid, Spain
Hosp. Univ. Pta. de Hierro Majadahonda
🇪🇸Majadahonda, Spain
ALTHAIA, Xarxa Assistencial Universitària de Manresa
🇪🇸Manresa, Spain
Hosp. de Navarra
🇪🇸Pamplona, Spain
Hosp. Virgen Macarena
🇪🇸Sevilla, Spain
Hosp. Virgen Del Rocio
🇪🇸Sevilla, Spain
Hosp. Gral. Univ. Valencia
🇪🇸Valencia, Spain
Hosp. Univ. I Politecni La Fe
🇪🇸Valencia, Spain
Hosp. Univ. Miguel Servet
🇪🇸Zaragoza, Spain
Kaohsiung Medical University Chung Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Chang Gung Medical Foundation
🇨🇳Niao-Sung Hsiang, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
Transkarpathian Regional University Oncology Clinic
🇺🇦Uzhgorod, Ukraine
Podilskiy Regional Center of Oncology
🇺🇦Vinnitsa, Ukraine
Zaokod
🇺🇦Zaporizhzhia, Ukraine
Zaporizhzhia medical Academy of postgraduate education, Zaporizhzhia Regoinal Clinical Hospital
🇺🇦Zaporizhzhia, Ukraine
University Hospitals Bristol - Bristol Haematology & Oncolog
🇬🇧Bristol, United Kingdom
St Bartholomew's Hospital
🇬🇧London, United Kingdom
Sarah Cannon Research Institute
🇬🇧London, United Kingdom
Charing Cross Hospital
🇬🇧London, United Kingdom
The Christie NHS Foundation Trust Christie Hospital
🇬🇧Manchester, United Kingdom
Derriford Hospital-Department of Medical Oncology
🇬🇧Plymouth, United Kingdom
University of Sheffield
🇬🇧Sheffield, United Kingdom
Southampton General Hospital
🇬🇧Southampton, United Kingdom
Royal Marsden Hospital
🇬🇧Sutton, United Kingdom
Alaska Urological Institute dba Alaska Clinical Research Center
🇺🇸Anchorage, Alaska, United States
University of Calif Davis Medical Center
🇺🇸Sacramento, California, United States
St. Helena Hospital - Martin-O'Neil Cancer Center
🇺🇸Saint Helena, California, United States
MedStar Georgetown University Hospital
🇺🇸Washington, District of Columbia, United States
University of Miami Sylvester Cancer Center
🇺🇸Miami, Florida, United States
Mid Florida Hematology Oncology
🇺🇸Orange, Florida, United States
Piedmont Cancer Institute
🇺🇸Atlanta, Georgia, United States
Rush University
🇺🇸Chicago, Illinois, United States
Edward Hines Jr V A Hospital
🇺🇸Hines, Illinois, United States
Norton Cancer Institute
🇺🇸Louisville, Kentucky, United States
Maryland Oncology Hematology, PA
🇺🇸Lanham, Maryland, United States
University of Michigan Health System
🇺🇸Ann Arbor, Michigan, United States
VA Sierra Nevada Health Care System
🇺🇸Reno, Nevada, United States
Dartmouth Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States
Weill Cornell Medical College
🇺🇸New York, New York, United States
Levine Cancer Institute, Carolinas HealthCare System
🇺🇸Charlotte, North Carolina, United States
W G Bill Hefner VA Medical Center
🇺🇸Salisbury, North Carolina, United States
Oncology Hematology Care
🇺🇸Cincinnati, Ohio, United States
The Center for Cancer and Blood Disorders
🇺🇸Fort Worth, Texas, United States
Texas Oncology-Memorial City
🇺🇸Houston, Texas, United States
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Texas Oncology Tyler
🇺🇸Tyler, Texas, United States
INOVA Dwiight &Martha Schar Cancer Institute
🇺🇸Fairfax, Virginia, United States
Virginia Oncology Associates
🇺🇸Norfolk, Virginia, United States
VA Puget Sound Healthcare System
🇺🇸Seattle, Washington, United States
Sociedade Beneficente de Senhoras Hospital Sirio Libanes
🇧🇷São Paulo, Brazil
Centro Oncológico Korben
🇦🇷Buenos Aires, Argentina
CEMIC Saavedra
🇦🇷Ciudad Autonoma de Buenos Aires, Argentina
Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
🇦🇷Cordoba, Argentina
Centro Urologico Profesor Bengio
🇦🇷Cordoba, Argentina
Hospital Privado de Comunidad
🇦🇷Mar Del Plata, Argentina
Centro de Investigacion Pergamino SA
🇦🇷Pergamino, Argentina
Clínica Viedma
🇦🇷Viedma, Argentina
Chris O'Brien Lifehouse
🇦🇺Camperdown, Australia
Peninsula & South Eastern Haematology and Oncology Group
🇦🇺Frankston, Australia
St George Hospital
🇦🇺Kogarah, Australia
Peter MacCallum Cancer Centre
🇦🇺Melbourne, Australia
Frankston Hospital
🇦🇺Melbourne, Australia
Fiona Stanley Hospital
🇦🇺Murdoch, Australia
LKH-Univ. Klinikum Graz
🇦🇹Graz, Austria
Ordensklinikum Linz GmbH Elisabethinen
🇦🇹Linz, Austria
LKH - Universitätsklinikum der PMU Salzburg
🇦🇹Salzburg, Austria
Krankenhaus der Barmherzigen Brüder
🇦🇹Vienna, Austria
Medical University Vienna MUV
🇦🇹Vienna, Austria
OLV Ziekenhuis Aalst
🇧🇪Aalst, Belgium
ZNA Middelheim
🇧🇪Antwerpen, Belgium
Cliniques Universitaires Saint Luc
🇧🇪Bruxelles, Belgium
Clinique Notre Dame de Grâce
🇧🇪Charleroi, Belgium
AZ Maria Middelares
🇧🇪Gent, Belgium
UZ Gent
🇧🇪Gent, Belgium
CHC MontLegia
🇧🇪Liege, Belgium
Sint-Augustinus AZ
🇧🇪Wilrijk, Belgium
CHU UCL Namur - Site Godinne
🇧🇪Yvoir, Belgium
Fundacao Pio XII
🇧🇷Barretos, Brazil
Universidade Federal De Minas Gerais - Hospital das Clínicas
🇧🇷Belo Horizonte, Brazil
Nucleo de Ensino e Pesquisa do Instituto Mario Penna
🇧🇷Belo Horizonte, Brazil
Instituto de Oncologia do Parana
🇧🇷Curitiba, Brazil
Liga Paranaense de Combate ao Cancer
🇧🇷Curitiba, Brazil
Associacao de Combate ao Cancer em Goias - Hospital de Cancer Araujo Jorge
🇧🇷Goiania, Brazil
Clínica de Neoplasias Litoral Ltda.
🇧🇷Itajai, Brazil
CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
🇧🇷Santo Andre, Brazil
UMHAT 'Dr. Georgi Stranski', EAD
🇧🇬Pleven, Bulgaria
Fundacao Doutor Amaral Carvalho
🇧🇷Jau, Brazil
Liga Norte Riograndense Contra O Cancer
🇧🇷Natal, Brazil
Hospital das Clinicas de Porto Alegre
🇧🇷Porto Alegre, Brazil
Hospital Nossa Senhora da Conceicao S A
🇧🇷Porto Alegre, Brazil
Ministerio da Saude Instituto Nacional do Cancer
🇧🇷Rio De Janeiro, Brazil
Oncoclinicas Rio de Janeiro S A
🇧🇷Rio de Janeiro, Brazil
Hospital Sao Rafael
🇧🇷Salvador, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
🇧🇷Sao Jose do Rio Preto, Brazil
Fundacao Antonio Prudente A C Camargo Cancer Center
🇧🇷Sao Paulo, Brazil
Instituto Brasileiro de Controle do Cancer - Sao Camilo Oncologia
🇧🇷Sao Paulo, Brazil
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
🇧🇷Sao Paulo, Brazil
Instituto de Oncologia de Sorocaba Onco Clinicas Especializadas
🇧🇷Sorocaba, Brazil
Complex Oncology Center - Plovdiv EOOD
🇧🇬Plovdiv, Bulgaria
Instituto D Or de Pesquisa e Ensino IDOR
🇧🇷São Paulo, Brazil
Multiprofile Hospital for Active Treatment 'Tokuda Hospital Sofia'
🇧🇬Sofia, Bulgaria
UMHAT Sofia Med
🇧🇬Sofia, Bulgaria
Multiprofile Hospital for Active Treatment 'Sveta Marina' EAD
🇧🇬Varna, Bulgaria
BC Cancer Agency - Southern Interior
🇨🇦Kelowna, British Columbia, Canada
Vancouver Cancer Centre
🇨🇦Vancouver, British Columbia, Canada
Cancercare Manitoba
🇨🇦Winnipeg, Manitoba, Canada
Thunder Bay Regional Health Sciences Centre
🇨🇦Thunder Bay, Ontario, Canada
Princess Margaret Hospital- UHN
🇨🇦Toronto, Ontario, Canada
Saskatchewan Cancer Agency (SCA) - Allan Blair Cancer Centre
🇨🇦Regina, Saskatchewan, Canada
Cancer Hospital Chinese Academy of Medical Sciences
🇨🇳Beijing, China
Peking University First Hospital
🇨🇳Beijing, China
Beijing Friendship Hospital
🇨🇳Beijing, China
Peking University Third Hospital
🇨🇳Beijing, China
Beijing Hospital
🇨🇳Beijing, China
Peking Union Medical College Hospital
🇨🇳Beijing, China
The First Bethune Hospital of Jilin University
🇨🇳Changchun, China
Sichuan Provincial Peoples Hospital
🇨🇳Chengdu, China
Sichuan University Huaxi Hospital
🇨🇳Chengdu, China
Chongqing University Cancer Hospital
🇨🇳ChongQing, China
Sun Yat Sen University Cancer Center
🇨🇳Guangzhou, China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
🇨🇳Guangzhou, China
Guangzhou First Municipal People's Hospital
🇨🇳Guangzhou, China
Zhejiang Provincial People's Hospital
🇨🇳Hangzhou, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
🇨🇳Hangzhou, China
Groupe Hospitalier Bretagne Sud
🇫🇷Lorient, France
The First Affliated Hospital Of Nanchang University
🇨🇳Nanchang, China
Nanjing Drum Tower Hospital
🇨🇳Nanjing, China
Jiangsu Cancer Hospital
🇨🇳Nanjing, China
Renji Hospital, Shanghai Jiaotong University School of Medicine
🇨🇳ShangHai, China
Huadong Hospital Affiliated to Fudan University
🇨🇳Shanghai, China
Shengjing Hospital Of China Medical University
🇨🇳Shenyang, China
Shenzhen university General Hospital
🇨🇳Shenzhen, China
First Affiliated Hospital Of Wenzhou Medical College
🇨🇳Wenzhou, China
The First Affiliated Hospital of Xian Jiaotong University
🇨🇳Xian, China
Institut de Cancerologie de l Ouest ICO
🇫🇷Angers, France
Hopital Jean Minjoz
🇫🇷Besancon Cedex, France
Institut Bergonie
🇫🇷Bordeaux, France
CHRU Brest - Hopital Morvan
🇫🇷Brest, France
Centre Jean Perrin
🇫🇷Clermont Ferrand, France
Centre Georges-François Leclerc
🇫🇷Dijon, France
Hôpital Privé Le Bois
🇫🇷Lille, France
Centre Oscar Lambret
🇫🇷Lille, France
Institut Regional du Cancer de Montpellier Val d'Aurelle
🇫🇷Montpellier, France
Centre Antoine Lacassagne
🇫🇷Nice, France
Institut de Cancérologie du Gard
🇫🇷Nîmes, France
Hospital Saint-Louis
🇫🇷Paris Cedex 10, France
Hopital Europeen Georges-Pompidou
🇫🇷Paris, France
Hospices Civils de Lyon HCL
🇫🇷Pierre-Bénite, France
CHU De Poitiers
🇫🇷Poitiers Cedex, France
Centre Eugene Marquis
🇫🇷Rennes Cedex, France
Centre de radiothérapie et d'Oncologie médicale de l'Essonne
🇫🇷Ris Orangis, France
Institut de Cancérologie de Loire
🇫🇷Saint-Priest-en-Jarez, France
Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
🇫🇷Strasbourg Cedex, France
Institut Claudius Regaud
🇫🇷Toulouse, France
Centre Les Dentellieres
🇫🇷Valenciennes, France
Institut Gustave Roussy
🇫🇷Villejuif, France
Vivantes Klinikum Am Urban
🇩🇪Berlin, Germany
Stadtisches Klinikum Braunschweig gGmbH-Klinik fur Urologie und Uroonkologie
🇩🇪Braunschweig, Germany
Universitatsklinikum Carl Gustav Carcus Dresden
🇩🇪Dresden, Germany
Universitaetsklinikum Duesseldorf
🇩🇪Duesseldorf, Germany
Friedrich-Alexander Universitaet Urologische Universitaetskl
🇩🇪Erlangen, Germany
Universitatsklinikum Frankfurt
🇩🇪Frankfurt, Germany
Universitatsklinikum Freiburg
🇩🇪Freiburg, Germany
Universitatsmedizin Gottingen
🇩🇪Gottingen, Germany
Universitätsmedizin Greifswald
🇩🇪Greifswald, Germany
Euromedica General Clinic
🇬🇷Thessaloniki, Greece
Papageorgiou General Hospital Of Thessaloniki
🇬🇷Thessaloniki, Greece
Semmelweis Egyetem
🇭🇺Budapest, Hungary
Országos Onkológiai Intézet, Urogenitális Tumorok és Klinikai Farmakológiai Osztály
🇭🇺Budapest, Hungary
Budapesti Uzsoki Utcai Korhaz
🇭🇺Budapest, Hungary
Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz
🇭🇺Nyíregyháza, Hungary
Pecsi Tudomanyegyetem Klinikai Kozpont
🇭🇺Pécs, Hungary
Rambam Health Care Campus
🇮🇱Haifa, Israel
Hadassah Medical Center
🇮🇱Jerusalem, Israel
Meir Medical Center
🇮🇱Kfar Saba, Israel
Rabin Medical Center, Beilinson Hospital
🇮🇱Petach Tikvah, Israel
Sourasky Medical Center
🇮🇱Tel Aviv, Israel
The Chaim Sheba Medical Center
🇮🇱Tel Hashomer, Israel
Assaf Harofeh Medical Center
🇮🇱Tzrifin, Israel
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo Alessandria
🇮🇹Alessandria, Italy
Ospedale S. Donato - Asl 8 Arezzo
🇮🇹Arezzo, Italy
CRO IRCCS Istituto Nazionale Tumori
🇮🇹Aviano, Italy
Azienda Ospedaliera Papa Giovanni XXIII
🇮🇹Bergamo, Italy
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
🇮🇹Brescia, Italy
Yamaguchi University Hospital
🇯🇵Ube, Japan
Yokohama City University Medical Center
🇯🇵Yokohama, Japan
Pusan National University Hospital
🇰🇷Busan, Korea, Republic of
Chungnam National University Hospital
🇰🇷Daejeon, Korea, Republic of
National Cancer Center
🇰🇷Goyangsi, Korea, Republic of
Chonnam National University Hospital
🇰🇷Gwangju, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Gyeonggi-do, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Kangbuk Samsung Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Yonsei University Wonju Severance Christian Hospital
🇰🇷Wonju-si, Korea, Republic of
Medicos Especialistas en Cancer, S.C.
🇲🇽Aguascalientes, Mexico
Centro Estatal de Cancerología de Chihuahua
🇲🇽Chihuahua, Mexico
Oncologia Integral Satelite
🇲🇽Naucalpan, Mexico
Antoni van Leeuwenhoek
🇳🇱Amsterdam, Netherlands
Haga ziekenhuis
🇳🇱Den Haag, Netherlands
St. Antonius Ziekenhuis Nieuwegein
🇳🇱Nieuwegein, Netherlands
Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy
🇵🇱Bydgoszcz, Poland
Centralny Szpital Kliniczny MSWiA w Warszawie
🇵🇱Warszawa, Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
🇵🇱Warszawa, Poland
Uniwersytecki Szpital Kliniczny we Wroclawiu
🇵🇱Wroclaw, Poland
Hospital Lusíadas
🇵🇹Lisboa, Portugal
H. Santa Maria - Centro Hospitalar de Lisboa Norte
🇵🇹Lisboa, Portugal
Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
🇵🇹Lisboa, Portugal
Champalimaud Foundation Champalimaud Centre
🇵🇹Lisbon, Portugal
Ivanovo Regional Oncology Dispensary
🇷🇺Ivanovo, Russian Federation
Kostroma regional oncology dispensary
🇷🇺Kostroma, Russian Federation
Leningrad Regional Oncology Dispensary
🇷🇺Kuzmolovsky, Russian Federation
City Clinical Hospital n.a. D.D.Pletnev
🇷🇺Moscow, Russian Federation
FSBSI 'N. N. Blokhin Russian Cancer Research Center'
🇷🇺Moscow, Russian Federation
Russian Scientific Center of Roentgenoradiology
🇷🇺Moscow, Russian Federation
I.M. Sechenov First Moscow State Medical University
🇷🇺Moscow, Russian Federation
Hertzen Oncology Research Institute
🇷🇺Moscow, Russian Federation
City Clinical Hospital #1
🇷🇺Nalchik, Russian Federation
Privolzhsky District Medical Center under the Federal Medico-Biological Agency
🇷🇺Nizhni Novgorod, Russian Federation
Clinical Oncology Dispensary
🇷🇺Omsk, Russian Federation
GBUZ of Stavropol region Pyatigorsk Oncological Dispensary
🇷🇺Pyatigorsk, Russian Federation
Private Medical Institution Euromedservice
🇷🇺Saint Petersburg, Russian Federation
Pavlov First Saint Petersburg State Medical University
🇷🇺Saint Petersburg, Russian Federation
LLC 'Strategic Medical Systems'
🇷🇺Saint-Petersburg, Russian Federation
Clinical hopital n/a Petra velikogo
🇷🇺Saint-Petersburg, Russian Federation
FGBOU Vo Mordovian National Research State University N. A. N.P. Ogareva
🇷🇺Saransk, Russian Federation
Saratov State Medical University
🇷🇺Saratov, Russian Federation
LLC Uromed
🇷🇺Smolensk, Russian Federation
GBUZ Oncology Centre #2 of Healthcare Department of Krasno
🇷🇺Sochi, Russian Federation
Russian Scientific Center of Radiology and Surgical Technologies
🇷🇺St. Petersburg, Russian Federation
Saint-Petersburg Clinical Scientific And Practical Center For Special Types Of Medical Care
🇷🇺St.Petersburg, Russian Federation
Multifunctional clinical medical center 'Medical city'
🇷🇺Tyumen, Russian Federation
Bashkiria State Medical University
🇷🇺Ufa, Russian Federation
Vologda Regional Oncological Dispensary
🇷🇺Vologda, Russian Federation
Hosp. Univ. Infanta Cristina
🇪🇸Badajoz, Spain
Institut Català D'Oncologia-Hospital Universitari Germans Trias I Pujol
🇪🇸Badalona, Spain
Hosp Clinic de Barcelona
🇪🇸Barcelona, Spain
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Chi Mei Medical Center Yong Kang
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei City, Taiwan
Mackay Memorial Hospital
🇨🇳Taipei, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Koo Foundation Sun Yat-Sen Cancer Center
🇨🇳Taipei, Taiwan
Chang-Gung Memorial Hospital, LinKou Branch
🇨🇳Taoyuan, Taiwan
Baskent University Adana Practice and Research Center Kisla Health Campus
🇹🇷Adana, Turkey
Hacettepe University Medical Faculty
🇹🇷Ankara, Turkey
Bezmialem University Medical Faculty
🇹🇷Istanbul, Turkey
Istanbul University Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Bakirkoy Training and Research Hospital
🇹🇷Istanbul, Turkey
Medipol Mega University Hospital
🇹🇷Istanbul, Turkey
T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
🇹🇷Istanbul, Turkey
Pendik Training and Research Hospital
🇹🇷Istanbul, Turkey
Ege University
🇹🇷Izmir, Turkey
Dokuz Eylul Universitesi Tip Fakultesi
🇹🇷Izmir, Turkey
Kocaeli University Medical Faculty
🇹🇷Kocaeli, Turkey
Inonu Universitesi Turgut Ozal Tip Merkezi, Ic Hastaliklari
🇹🇷Malatya, Turkey
MI Dnipropetrovsk Region Clinical Hospital n a I.I.Mechnikov
🇺🇦Dnipropetrovsk, Ukraine
Municipal Institution 'Clinical Oncology Dispensary' Under Dnipropetrovsk Regional Council
🇺🇦Dnipro, Ukraine
Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
🇺🇦Dnipro, Ukraine
Ivano-Frankivsk Regional Clinical Hospital
🇺🇦Ivano-Frankivsk, Ukraine
Regional Medical Clinical Center for Urology and Nephrology named after V.I. Shapoval
🇺🇦Kharkiv, Ukraine
Municipal non-profit enterprise 'Regional Center of Oncology'
🇺🇦Kharkiv, Ukraine
National Cancer Institute
🇺🇦Kyiv, Ukraine
State Institution Institute of Urology NAMS of Ukraine based on Kyiv City Clinical Oncology Center
🇺🇦Kyiv, Ukraine
Communal Noncommercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital'
🇺🇦Lviv, Ukraine